Press briefing on PRAC conclusions on signal of thromboembolic events with COVID-19 Vaccine Janssen
EMA is holding a virtual press briefing on the conclusion of the evaluation of a safety signal with Jcovden (previously COVID-19 Vaccine Janssen) relating to cases of thromboembolic events by EMA’s safety committee, the Pharmacovigilance Risk Assessment Committee (PRAC), on 20 April 2021.
- Ms Emer Cooke (Executive Director)
- Dr Sabine Straus (Chair of PRAC)
- Dr Peter Arlett (Head of Data Analytics and Methods Task Force).
The press briefing will be moderated by Ms Marie-Agnes Heine (Head of Communication).
The press briefing will be held in English.